NO975080L - Inhibitorer av fibrintverrbinding og/eller transglutaminaser - Google Patents
Inhibitorer av fibrintverrbinding og/eller transglutaminaserInfo
- Publication number
- NO975080L NO975080L NO975080A NO975080A NO975080L NO 975080 L NO975080 L NO 975080L NO 975080 A NO975080 A NO 975080A NO 975080 A NO975080 A NO 975080A NO 975080 L NO975080 L NO 975080L
- Authority
- NO
- Norway
- Prior art keywords
- pro
- inhibitors
- leu
- lys
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Inhibitorene, som kan oppnås fra vev eller sekreter av blodigler typisk av ordenen Rhynchobdellida, har følgende terminalsekvens: NH2-Lys-Leu-Leu-Pro-Cys-Lys-Glu-Y-His-Gln-Gly-Ile-Pro-Asn-Pro-Arg- hvor Y representerer en hvilken som helst aminosyresekvens; eller et farmasøytisk akseptabelt salt, derivat eller bioforløper av nevnte sekvens, eller en analog eller homolog derav. På grunn av deres ekstreme virkningsgrad i det nanomolare området kan de anvendes for behandling av en rekke sykdommer der proteintverrbinding er viktig. De kan anvendes for behandling av Crohn's sykdom tumorimplantasjon, atero sklerose, trombotisk mikroangiopati, fibrøse vekster i huden, åene, arrdannelse, membranøs glomerulonefritt, katarakter, eller infeksjon med mikrofilareale nematoder. De kan spesielt anvendes for å redusere stabiliteten av tromber slik at de er mer mottakelige for lysering med trombolytiske midler.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9509271.4A GB9509271D0 (en) | 1995-05-05 | 1995-05-05 | Blood clot stabilisation inhibitors |
PCT/GB1996/001093 WO1996034890A2 (en) | 1995-05-05 | 1996-05-07 | Inhibitors of fibrin cross-linking and/or transglutaminases |
Publications (2)
Publication Number | Publication Date |
---|---|
NO975080D0 NO975080D0 (no) | 1997-11-04 |
NO975080L true NO975080L (no) | 1998-01-02 |
Family
ID=10774108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO975080A NO975080L (no) | 1995-05-05 | 1997-11-04 | Inhibitorer av fibrintverrbinding og/eller transglutaminaser |
Country Status (14)
Country | Link |
---|---|
US (1) | US6025330A (no) |
EP (1) | EP0848719A2 (no) |
JP (1) | JPH11505218A (no) |
KR (1) | KR19990008348A (no) |
AU (1) | AU723130B2 (no) |
BR (1) | BR9608207A (no) |
CA (1) | CA2220268A1 (no) |
CZ (1) | CZ348197A3 (no) |
GB (1) | GB9509271D0 (no) |
HU (1) | HUP9900408A3 (no) |
NO (1) | NO975080L (no) |
PL (1) | PL323252A1 (no) |
SK (1) | SK148797A3 (no) |
WO (1) | WO1996034890A2 (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998056409A1 (en) * | 1997-06-11 | 1998-12-17 | Smithkline Beecham Corporation | USE OF FACTOR XIIIa INHIBITORS TO TREAT ATHEROSCLEROSIS |
DE10046187A1 (de) * | 2000-09-13 | 2002-03-21 | Univ Schiller Jena | Verfahren zur Messung der Aktivität von Gerinnungsfaktor XIIIa |
AU2002366874A1 (en) * | 2001-12-21 | 2003-07-09 | Curacyte Ag | Modified tridegins, production and use thereof as transglutaminase inhibitors |
DE10163333B4 (de) * | 2001-12-21 | 2007-01-25 | Curacyte Ag | Modifizierte Tridegine, ihre Herstellung deren Verwendung als Transglutaminase Inhibitoren und diese enthaltende Arzneimittel und Kombinationspräparate |
JP2009510105A (ja) * | 2005-09-28 | 2009-03-12 | バイオバスキュラー インコーポレーティッド | 血小板および細胞の接着、細胞移動、および炎症を阻止するための方法および組成物 |
US20110034396A1 (en) * | 2005-09-28 | 2011-02-10 | Biovascular, Inc. | Methods and compositions for inhibiting cell migration and treatment of inflammatory conditions |
US20100316764A1 (en) * | 2009-06-10 | 2010-12-16 | Engrain, LLC | Flour supplement compositions and methods for preparing wheat flour |
GB201318182D0 (en) * | 2013-10-14 | 2013-11-27 | Univ Nottingham Trent | Inhibitor peptides |
KR102131041B1 (ko) | 2013-12-03 | 2020-07-08 | (주)아모레퍼시픽 | 태양광 차단 기능성 물질 스크리닝 방법 및 태양광 차단 효능 평가 방법 |
WO2017089961A1 (pt) * | 2015-11-24 | 2017-06-01 | Universidade De Trás-Os-Montes E Alto Douro | Método para a produção de farinhas de cereais e de proteínas enriquecidas em l-teanina e respectivos produtos |
TWI825144B (zh) | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
CN110174513A (zh) * | 2019-04-15 | 2019-08-27 | 中山大学附属第一医院 | Tgm2在制备监测克罗恩病疾病活动的生物标志物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0347376B1 (en) * | 1988-06-11 | 1994-03-23 | Ciba-Geigy Ag | Novel polypeptides with an anticoagulant activity |
US5227469A (en) * | 1990-02-14 | 1993-07-13 | Genentech, Inc. | Platelet aggregation inhibitors from the leech |
US5328898A (en) * | 1990-06-22 | 1994-07-12 | Duke University | Factor XIIIA fibrin binding fragments |
WO1992013530A1 (en) * | 1991-02-11 | 1992-08-20 | Medicis Corporation | Transglutaminase enzyme inhibitors |
IT1264084B1 (it) * | 1993-12-22 | 1996-09-10 | Raggio Italgene Spa | Peptide ad attivita' di substrato e/o inibitore dell'enzima transglutaminasi e suo uso in diagnosi e terapia. |
DE4402631A1 (de) * | 1994-01-29 | 1995-08-03 | Boehringer Mannheim Gmbh | Verfahren zur Bestimmung von Gerinnungsparametern |
-
1995
- 1995-05-05 GB GBGB9509271.4A patent/GB9509271D0/en active Pending
-
1996
- 1996-05-07 SK SK1487-97A patent/SK148797A3/sk unknown
- 1996-05-07 CZ CZ973481A patent/CZ348197A3/cs unknown
- 1996-05-07 AU AU56546/96A patent/AU723130B2/en not_active Ceased
- 1996-05-07 EP EP96913623A patent/EP0848719A2/en not_active Withdrawn
- 1996-05-07 KR KR1019970707874A patent/KR19990008348A/ko not_active Application Discontinuation
- 1996-05-07 HU HU9900408A patent/HUP9900408A3/hu unknown
- 1996-05-07 US US08/009,459 patent/US6025330A/en not_active Expired - Fee Related
- 1996-05-07 BR BR9608207-0A patent/BR9608207A/pt not_active Application Discontinuation
- 1996-05-07 PL PL96323252A patent/PL323252A1/xx unknown
- 1996-05-07 CA CA002220268A patent/CA2220268A1/en not_active Abandoned
- 1996-05-07 JP JP8533139A patent/JPH11505218A/ja active Pending
- 1996-05-07 WO PCT/GB1996/001093 patent/WO1996034890A2/en not_active Application Discontinuation
-
1997
- 1997-11-04 NO NO975080A patent/NO975080L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR19990008348A (ko) | 1999-01-25 |
SK148797A3 (en) | 1998-04-08 |
CA2220268A1 (en) | 1996-11-07 |
HUP9900408A2 (hu) | 1999-05-28 |
PL323252A1 (en) | 1998-03-16 |
NO975080D0 (no) | 1997-11-04 |
WO1996034890A2 (en) | 1996-11-07 |
MX9708513A (es) | 1998-08-30 |
AU5654696A (en) | 1996-11-21 |
EP0848719A2 (en) | 1998-06-24 |
CZ348197A3 (cs) | 1998-03-18 |
US6025330A (en) | 2000-02-15 |
AU723130B2 (en) | 2000-08-17 |
WO1996034890A3 (en) | 1997-10-23 |
JPH11505218A (ja) | 1999-05-18 |
BR9608207A (pt) | 2000-10-31 |
GB9509271D0 (en) | 1995-06-28 |
HUP9900408A3 (en) | 2001-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO975080L (no) | Inhibitorer av fibrintverrbinding og/eller transglutaminaser | |
Laato et al. | Stimulation of wound healing by epidermal growth factor. A dose-dependent effect. | |
DE69430315T2 (de) | Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl | |
NO20006078L (no) | N-bundete sulfen-amider av N-heterocykliske karboksylsyrer eller karboksylsyre-isostere | |
DE69324151D1 (de) | Inhibitoren des arginin-ketoamid-enzyms | |
WO2002002593A3 (en) | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof | |
JPH04211019A (ja) | 創傷治癒促進のためのトロンボスポンデインの使用 | |
ES2129426T3 (es) | Polipeptidos antitrombinicos. | |
DE68904462T2 (de) | 4-chinolincarbonsaeure-derivate, brauchbar zur behandlung von haut- und muco-epithelial-gewebekrankheiten. | |
EA200001124A1 (ru) | Способ генной терапии | |
ATE359798T1 (de) | Verwendungvon dextransulfat zur behandlung von ibmir | |
NO974260L (no) | Nye definerte enzymblandinger for oppnåelse av celler og behandling av sår | |
ATE369856T1 (de) | Verfahren zur behandlung von glaukom | |
ATE321045T1 (de) | Methoden und zusammensetzungen zur behandlung von schmerzen | |
RU2002135669A (ru) | Олигопептиды | |
Peacock | Collagenolysis: The other side of the equation | |
Collier | LXIV The Present Position of Facial Nerve Surgery | |
NO980300L (no) | Nye höymolekylære humane MP52 proteiner | |
NO995692D0 (no) | Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse | |
ATE374048T1 (de) | Verwendung von matrixprotein für gesteuerte geweberegenerationen | |
US6340458B1 (en) | Use of enzymes for skin expansion | |
ATE319740T1 (de) | Verfahren zur gewinnung und anwendung von antibiotisch wirksamen peptiden zur behandlung von infektionskrankheiten | |
RU2192814C1 (ru) | Способ лечения эпителиальных ран роговицы | |
ATE203680T1 (de) | Konjugat zur behandlung von entzündungserkrankungen | |
DE69904712D1 (de) | Verwendung von deltorphin zur behandlung von zytokin-vermittelter leberschädigung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |